Literature DB >> 28190955

Multi-level Correlates of Safer Conception Methods Awareness and Attitudes Among Ugandan HIV Clients with Fertility Intentions.

Glenn J Wagner1, Mahlet A Woldetsadik1, Jolly Beyeza-Kashesya2, Kathy Goggin3, Deborah Mindry4, Sarah Finocchario-Kessler5, Sarah Khanakwa6, Rhoda K Wanyenze7.   

Abstract

Many people living with HIV desire childbearing, but low cost safer conception methods (SCM) such as timed unprotected intercourse (TUI) and manual self-insemination (MSI) are rarely used. We examined awareness and attitudes towards SCM, and the correlates of these constructs among 400 HIV clients with fertility intentions in Uganda. Measures included awareness, self-efficacy, and motivation regarding SCM, as well as demographics, health management, partner and provider characteristics. Just over half knew that MSI (53%) and TUI (51%) reduced transmission risk during conception, and 15% knew of sperm washing and pre-exposure prophylaxis. In separate regression models for SCM awareness, motivation, and self-efficacy, nearly all independent correlates were related to the partner, including perceived willingness to use SCM, knowledge of respondent's HIV status, HIV-seropositivity, marriage and equality in decision making within the relationship. These findings suggest the importance of partners in promoting SCM use and partner inclusion in safer conception counselling.

Entities:  

Keywords:  manual self-insemination; self-efficacy; timed unprotected intercourse

Mesh:

Year:  2016        PMID: 28190955      PMCID: PMC5297376          DOI: 10.29063/ajrh2016/v20i1.4

Source DB:  PubMed          Journal:  Afr J Reprod Health        ISSN: 1118-4841


  32 in total

1.  Sexual behavior of HIV discordant couples after HIV counseling and testing.

Authors:  Susan Allen; Jareen Meinzen-Derr; Michele Kautzman; Isaac Zulu; Stanley Trask; Ulgen Fideli; Rosemary Musonda; Francis Kasolo; Feng Gao; Alan Haworth
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

2.  The role of self-efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES).

Authors:  Mallory O Johnson; Torsten B Neilands; Samantha E Dilworth; Stephen F Morin; Robert H Remien; Margaret A Chesney
Journal:  J Behav Med       Date:  2007-06-23

3.  Strategies for harm reduction among HIV-affected couples who want to conceive.

Authors:  Lynn T Matthews; Joia S Mukherjee
Journal:  AIDS Behav       Date:  2009-04-04

4.  HIV treatment as prevention--it works.

Authors: 
Journal:  Lancet       Date:  2011-05-21       Impact factor: 79.321

5.  Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.

Authors:  Louise C Ivers; David Kendrick; Karen Doucette
Journal:  Clin Infect Dis       Date:  2005-05-27       Impact factor: 9.079

6.  Strategy to accelerate progress towards the attainment of international development goals and targets related to reproductive health.

Authors: 
Journal:  Reprod Health Matters       Date:  2005-05

7.  Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services.

Authors:  Diane Cooper; Jennifer Moodley; Virginia Zweigenthal; Linda-Gail Bekker; Iqbal Shah; Landon Myer
Journal:  AIDS Behav       Date:  2009-04-03

8.  Providing fertility care to men seropositive for human immunodeficiency virus: reviewing 10 years of experience and 420 consecutive cycles of in vitro fertilization and intracytoplasmic sperm injection.

Authors:  Mark V Sauer; Jeff G Wang; Nataki C Douglas; Gary S Nakhuda; Pratibashri Vardhana; Vuk Jovanovic; Michael M Guarnaccia
Journal:  Fertil Steril       Date:  2008-06-13       Impact factor: 7.329

Review 9.  Evaluating safer conception options for HIV-serodiscordant couples (HIV-infected female/HIV-uninfected male): a closer look at vaginal insemination.

Authors:  Okeoma Mmeje; Craig R Cohen; Deborah Cohan
Journal:  Infect Dis Obstet Gynecol       Date:  2012-08-08

10.  Fertility and contraceptive decision-making and support for HIV infected individuals: client and provider experiences and perceptions at two HIV clinics in Uganda.

Authors:  Rhoda K Wanyenze; Glenn J Wagner; Nazarius M Tumwesigye; Maria Nannyonga; Fred Wabwire-Mangen; Moses R Kamya
Journal:  BMC Public Health       Date:  2013-02-02       Impact factor: 3.295

View more
  5 in total

1.  'I'm waiting for that': Interest in the use of PrEP for safer conception in Botswana.

Authors:  Sarah A Gutin; Gary W Harper; K Rivet Amico; Christina Bitsang; Neo Moshashane; Jane Harries; Doreen Ramogola-Masire; Chelsea Morroni
Journal:  Glob Public Health       Date:  2020-03-16

2.  A Systematic Review of the Current Status of Safer Conception Strategies for HIV Affected Heterosexual Couples in Sub-Saharan Africa.

Authors:  D Joseph Davey; S West; V Umutoni; S Taleghani; H Klausner; E Farley; R Shah; S Madni; S Orewa; V Kottamasu; V Rice; Z Robbin; K M Wall
Journal:  AIDS Behav       Date:  2018-09

3.  Predictors of Safer Conception Practices Among HIV-Infected Women in Northern Nigeria.

Authors:  Zubairu Iliyasu; Hadiza S Galadanci; Alfa I Oladimeji; Musa Babashani; Auwalu U Gajida; Muktar H Aliyu
Journal:  Int J Health Policy Manag       Date:  2019-08-01

4.  "I did not know about all these": Perceptions regarding safer conception methods by women living with HIV in Gaborone, Botswana.

Authors:  Sarah A Gutin; Gary W Harper; Neo Moshashane; Kehumile Ramontshonyana; Atlang Mompe; Paul J Fleming; Jane Harries; Doreen Ramogola-Masire; Chelsea Morroni
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

5.  Relationship, partner factors and stigma are associated with safer conception information, motivation, and behavioral skills among women living with HIV in Botswana.

Authors:  Sarah A Gutin; Gary W Harper; Neo Moshashane; Kehumile Ramontshonyana; Rob Stephenson; Starley B Shade; Jane Harries; Okeoma Mmeje; Doreen Ramogola-Masire; Chelsea Morroni
Journal:  BMC Public Health       Date:  2021-12-08       Impact factor: 4.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.